(Date:5/16/2008)...nce-promising drug formerly approved as a second l...a, enhanced the effectiveness of hormonal therapy ...breast cancer, according to a Phase II clinical tr...M. D. Anderson Cancer Center. , These findings a...dy for Iressa in breast cancer, as well as for the...
(Date:5/16/2008)...USNewswire/ -- Behavioral healthcare,systems are p...the millions,of Americans of all ages who experien...ear, according to the latest annual survey from th...ms (NAPHS) released today., The 2007 NAPHS Annual...healthcare delivery. One chapter provides a trend ...
(Date:5/16/2008)...of Nomura Code Securities Limited as ... May 16 /PRNewswire-FirstCall/ -- Medicsight PLC, ...x: MGT ) (the "Company"), and an,industry leader ...D) and,image analysis software which assists in th...announced the appointment of NM Rothschild & Sons ...
(Date:5/16/2008)...wire/ -- Tao Formulations announces the,official l...t the Internal,Medicine 2008 conference in Washing...ion of years of research to develop a safe, all-na...r relieving menopausal symptoms., Company founder...ician,and gynecologist, founded Tao Formulations ...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2(Date:5/15/2008)... BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCall...announced today that findings from the,landmark AT...tial therapy,for the treatment of patients with at... risk of cardiovascular hospitalizations or death ...(p=0.00000002), meeting the study,primary endpoint...
(Date:5/15/2008)... BOSTON, May 15 /- CenterWatch, a p... on market research about clinical,trials, finds t...iple EDC,(electronic data capture) systems. More t...vey indicated that they had been trained on three ...ated that the effectiveness of,their EDC training ...
(Date:5/15/2008)...edicare Advantage Fee-For-Service Plan Positions B...Business, According to a New Report from ..., Tenn., May 15 /- HealthLeaders-Inte...t intelligence, reports that as the,economy contin...d of,Michigan remains the best equipped of all of ...
(Date:5/15/2008)... GREEN BAY, Wis., May 15 /- Omega 3... further considered as a credible natural,alternat...in ADHD patients,recent in vivo French study reve...l effects of omega-3 in hyperactivity, French rese...have specific positive effects on,impulse control....
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3A unique experiment with chlorine and a new way of teaching 948 1New technique improves purity of medicines 4493 1New technique improves purity of medicines 4493 2Twinkle eye test could improve AMD diagnosis 4491 1Twinkle eye test could improve AMD diagnosis 4491 2Bodys Clock Never Adjusts to Daylight Savings Time 4489 1Bodys Clock Never Adjusts to Daylight Savings Time 4489 2Bodys Clock Never Adjusts to Daylight Savings Time 4489 3...FirstCall/ --,Bionovo, Inc.,s lead drug candidate,...eatment of hot flashes associated with menopause.,...he company,s,double-blind, placebo- controlled, ra...50 or more moderate to severe hot flashes,per week...receiving,MF101 (5 grams/day), MF101 (10 grams/day...
...rstCall/ -- VION,PHARMACEUTICALS, INC. announced t... session at the 43rd Annual Meeting of The America...anticancer agent,Cloretazine(R) (VNP40101M) as a s...elapsed or refractory small cell lung cancer. , Th...1M) in two,separate subpopulations of small cell l...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4The Mitek CuffTack sutureless fixation device offers superior fixation strength for rotator cuff repairs. The implant firmly reattaches soft tissue to the bone with one step insertion. CuffTack is in
...imple to use system can be used for open or arthro... a sterile disposable inserter. The unique deploym... insertion of the anchor into bone. The Independe...lows for the two pre-threaded sutures to independe...
The Micro Anchor is the smallest, strongest anchor on the market allowing exceptional flexibility in placement into even the smallest bones. This anchor comes pre-loaded with 3-0 or 4-0 ETHIBOND EXCE
FASTIN RC is a threaded titanium anchor, specifically designed for rotator cuff procedures. The anchor features wide threads and a small core to optimize bone purchase, as well as independent suture
Medicine Products: